Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)

NCT07627347 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

ESCC

Interventions

DRUG: anlotinib+bevacizumab

Sponsor

Nanfang Hospital, Southern Medical University